Literature DB >> 7278650

Urinary 3-methylhistidine/creatinine ratio as a clinical tool: correlation between 3-methylhistidine excretion and metabolic and clinical states in healthy and stressed premature infants.

J H Seashore, G Huszar, E M Davis.   

Abstract

We have investigated the role of the urinary 3-methylhistidine (3MH) excretion, a measure of protein catabolism, in the evaluation of the metabolic state of premature infants. Two-hundred and twenty-two 24 hr urine collections and 3MH/Cr ratio determinations (expressed as mumoles of 3MH per mg creatinine) were carried out in 36 infants (average gestational age 32.7 +/- 0.7 wk, weight 1640 +/- 120 grams) and the relationship between the 3MH/Cr ratios and the metabolic and clinical state has been investigated. Five or more 3MH/Cr measurements were carried out on each of 19 infants and serial determinations on four of those babies are presented. The urinary 3MH/Cr ratio of healthy infants with adequate caloric intake and normal growth curve was .148 +/- .039 (S.D.) mumol/mg, about 35% higher than the 3MH/Cr ratio in healthy adults. As long as the premature infants were healthy the degree of prematurity had no effect on the 3MH/Cr ratio. The relationship between 3MH/Cr ratio and nitrogen balance was highly significant (p less than .001). 3MH/Cr ratio also correlates very well with the metabolic status of the infants: in the group with normal 3MH/Cr ratios less than or equal to .175 (.148 + 1 S.D., n = 90) there were four clinically stressed infants (4.4% false negative rate) while in the group with elevated 3MH/Cr ratios greater than .225 (.148 + 2 S.D.; n = 79) there were only three clinically well infants (3.8% false positive rate). In comparing the clinical status and 3MH/Cr ratios, we found that in the group of infants who could not be clearly defined as clinically well or stressed (n = 108) the 3MH/Cr ratio was more useful than clinical judgment in the prediction of metabolic status. It can be concluded that 3MH/Cr ratio is a potentially useful clinical tool which describes with high accuracy the clinical and metabolic status of premature infants. This conclusion is further supported by the data of serial 3MH/Cr determinations.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7278650     DOI: 10.1016/0026-0495(81)90093-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  4 in total

1.  Tight Glycemic Control With Insulin Does Not Affect Skeletal Muscle Degradation During the Early Postoperative Period Following Pediatric Cardiac Surgery.

Authors:  Jeremy G Fisher; Eric A Sparks; Faraz A Khan; Jamin L Alexander; Lisa A Asaro; David Wypij; Michael Gaies; Biren P Modi; Christopher Duggan; Michael S D Agus; Yong-Ming Yu; Tom Jaksic
Journal:  Pediatr Crit Care Med       Date:  2015-07       Impact factor: 3.624

2.  Muscle proteolysis and weight loss in a neonatal rat model of sepsis syndrome.

Authors:  D M Premer; R Goertz; M K Georgieff; M C Mammel; S J Schwarzenberg
Journal:  Inflammation       Date:  2002-04       Impact factor: 4.092

3.  Catabolic effect of dexamethasone in the preterm baby.

Authors:  K G Brownlee; P C Ng; M J Henderson; M Smith; J H Green; P R Dear
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

4.  The impact of sarcopenia and acute muscle mass loss on long-term outcomes in critically ill patients with intra-abdominal sepsis.

Authors:  Michael C Cox; Matthew Booth; Gabriela Ghita; Zhongkai Wang; Anna Gardner; Russell B Hawkins; Dijoia B Darden; Christiaan Leeuwenburgh; Lyle L Moldawer; Frederick A Moore; Philip A Efron; Steven Anton; Scott C Brakenridge
Journal:  J Cachexia Sarcopenia Muscle       Date:  2021-06-30       Impact factor: 12.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.